Lorenzo Diane, Gallois Claire, Lahmek Pierre, Lesgourgues Bruno, Champion Christine, Charpignon Claire, Faroux Roger, Bour Bruno, Remy André-Jean, Naouri Chantal, Picon Magali, Poncin Eric, Macaigne Gilles, Seyrig Jacques-Arnaud, Bernardini David, Bellaïche Guy, Grasset Denis, Henrion Jean, Heluwaert Frédéric, Piperaud René, Bordes Gilbert, Bourhis Francois, Arpurt Jean-Pierre, Pariente Alexandre, Nahon Stéphane
Service d'Hépato-Gastroentérologie. Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France.
Service d'addictologie. Hôpital Emile Roux AP-HP, Limeil-Brévannes, France.
United European Gastroenterol J. 2017 Feb;5(1):119-127. doi: 10.1177/2050640616647816. Epub 2016 Jun 23.
The aim of this study was to determine the mortality and re-bleeding rates, and the risk factors involved, in a cohort of patients with previous diverticular bleeding (DB).
In 2007, data on 2462 patients with lower gastrointestinal (GI) bleeding were collected prospectively at several French hospitals. We studied the follow-up of patients with DB retrospectively. The following data were collected: age, mortality rates and re-bleeding rates, drug intake, surgery and comorbidities.
Data on 365 patients, including 181 women (mean age 83.6 ± 9.8 years) were available. The median follow-up time was 3.9 years (IQR 25-75: 1.7-5.4). Of these, 148 patients died (40.5%). Among the 70 patients (19.2%) who had at least one re-bleeding episode, nine died and three underwent surgical procedures. Anticoagulation and antiplatelet therapy was discontinued in 70 cases (19.2%). The independent risk factors contributing to mortality were age > 80 years (HR = 3.18 (2.1-4.9); < 0.001) and a Charlson comorbidity score > 2 (1.91 (1.31-2.79); = 0.003). Discontinuation of therapy was not significantly associated with a risk of death due to cardiovascular events. No risk factors responsible for re-bleeding were identified, such as antiplatelet and anticoagulant therapy in particular.
In this cohort, the rates of mortality and DB re-bleeding after a median follow-up time of 3.9 years were 19.2% and 40.5%, respectively. The majority of the deaths recorded were not due to re-bleeding.
本研究旨在确定既往有憩室出血(DB)患者队列中的死亡率、再出血率及相关危险因素。
2007年,法国多家医院前瞻性收集了2462例下消化道(GI)出血患者的数据。我们对DB患者的随访情况进行了回顾性研究。收集了以下数据:年龄、死亡率、再出血率、药物服用情况、手术及合并症。
共有365例患者的数据可用,其中包括181名女性(平均年龄83.6±9.8岁)。中位随访时间为3.9年(四分位间距25 - 75:1.7 - 5.4)。其中,148例患者死亡(40.5%)。在至少有一次再出血事件的70例患者(19.2%)中,9例死亡,3例接受了手术。70例(19.2%)患者停用了抗凝和抗血小板治疗。导致死亡的独立危险因素为年龄>80岁(HR = 3.18(2.1 - 4.9);P<0.001)和Charlson合并症评分>2(1.91(1.31 - 2.79);P = 0.003)。治疗中断与心血管事件导致的死亡风险无显著相关性。未发现导致再出血的危险因素,尤其是抗血小板和抗凝治疗。
在此队列中,中位随访3.9年后,死亡率和DB再出血率分别为40.5%和19.2%。记录的大多数死亡并非由再出血所致。